273 related articles for article (PubMed ID: 33035140)
1. Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer?
Patel A
J Urol; 2021 Mar; 205(3):806-811. PubMed ID: 33035140
[TBL] [Abstract][Full Text] [Related]
2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
[TBL] [Abstract][Full Text] [Related]
5. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.
Kamada S; Sakamoto S; Ando K; Muroi A; Fuse M; Kawamura K; Imamoto T; Suzuki H; Nagata M; Nihei N; Akakura K; Ichikawa T
J Urol; 2015 Nov; 194(5):1264-70. PubMed ID: 25861958
[TBL] [Abstract][Full Text] [Related]
6. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer.
Bertaglia V; Tucci M; Fiori C; Aroasio E; Poggio M; Buttigliero C; Grande S; Saini A; Porpiglia F; Berruti A
Clin Genitourin Cancer; 2013 Sep; 11(3):325-330.e1. PubMed ID: 23531429
[TBL] [Abstract][Full Text] [Related]
7. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
Takei A; Sakamoto S; Wakai K; Tamura T; Imamura Y; Xu M; Maimaiti M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Int J Urol; 2018 Apr; 25(4):352-358. PubMed ID: 29323427
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
9. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
10. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Regis L; Planas J; Carles J; Maldonado X; Comas I; Ferrer R; Morote J
Prostate; 2017 Jan; 77(1):114-120. PubMed ID: 27800640
[TBL] [Abstract][Full Text] [Related]
11. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
12. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
13. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
14. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract][Full Text] [Related]
15. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.
Roach M; Bae K; Lawton C; Donnelly BJ; Grignon D; Hanks GE; Porter A; Lepor H; Venketesan V; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1314-22. PubMed ID: 20378270
[TBL] [Abstract][Full Text] [Related]
16. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
17. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
[TBL] [Abstract][Full Text] [Related]
18. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
[TBL] [Abstract][Full Text] [Related]
20. Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.
Sayyid RK; Sayyid AK; Klaassen Z; Fadaak K; Goldberg H; Chandrasekar T; Ahmad A; Leao R; Perlis N; Chadwick K; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta AR; Fleshner NE
J Urol; 2018 Jan; 199(1):251-256. PubMed ID: 28751266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]